Skip to Content
Stock Analyst Update

Pfizer Steady, Shares Look Undervalued

We continue to view this wide-moat stock as undervalued and maintain our fair value estimate.


Pfizer (PFE) reported steady first-quarter results slightly ahead of our and S&P CapIQ consensus expectations, but we don’t expect any major changes to our fair value estimate based on the minor outperformance. We continue to view the stock as undervalued with the market not likely fully appreciating the firm’s entrenched portfolio and growing pipeline, which also supports its wide moat.

In the quarter, total sales fell 1% operationally (excluding the consumer joint venture) due to Chinese pricing pressures and generic competition to neuroscience drug Lyrica, but we expect growth will accelerate going into 2021 as these issues annualize. Also, several entrenched drugs should continue to post gains, including cancer drug Ibrance (up 11%) as new indications in earlier lines of therapy are likely following data expected by year-end. Cardiovascular drug Eliquis (up 29% aided by some stocking) should take more share from warfarin, which needs more intensive doctor monitoring. Also, Pfizer’s pneumococcal vaccine Prevnar 13 (down 1% partly due to lumpy government purchases) is holding up well despite coronavirus concerns potentially keeping patients out of doctors’ offices. While we expect some slowing with new drugs Xtandi (cancer), Vyndamax (cardiology), and Braftovi/Mektovi (cancer) as sales teams and doctors are disrupted by the coronavirus, we still expect gains due to the severity of the underlying diseases. We remain bullish on Pfizer’s immunology pipeline, led by abrocitinib, which recently showed superior data versus competing atopic dermatitis leader Dupixent.

On the restructuring side, Pfizer is making progress to sell its generic drug group Upjohn to Mylan in the second half of 2020 (delayed from mid-2020 due to coronavirus disruptions). We expect the transaction will largely create net neutral synergies but should not cause valuation destruction, which was implied by the market reaction to the initial news of this transaction in late July 2019.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.